Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Total Non-Current Liabilities (2016 - 2025)

Macrogenics (MGNX) has disclosed Total Non-Current Liabilities for 13 consecutive years, with $200.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 39.39% to $200.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $200.2 million, a 39.39% increase, with the full-year FY2025 number at $200.2 million, up 39.39% from a year prior.
  • Total Non-Current Liabilities was $200.2 million for Q4 2025 at Macrogenics, down from $202.4 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $234.0 million in Q1 2023 to a low of -$258000.0 in Q3 2022.
  • A 5-year average of $133.4 million and a median of $142.5 million in 2024 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: crashed 100.26% in 2022, then soared 56586.05% in 2023.
  • Macrogenics' Total Non-Current Liabilities stood at $95.4 million in 2021, then soared by 44.91% to $138.2 million in 2022, then rose by 5.32% to $145.5 million in 2023, then dropped by 1.32% to $143.6 million in 2024, then skyrocketed by 39.39% to $200.2 million in 2025.
  • Per Business Quant, the three most recent readings for MGNX's Total Non-Current Liabilities are $200.2 million (Q4 2025), $202.4 million (Q3 2025), and $197.1 million (Q2 2025).